Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 63Ovarian Neoplasms 8Neoplasm Metastasis 8Endometrial Neoplasms 6Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms by Site 3Colorectal Neoplasms 3Breast Diseases 3Small Cell Lung Carcinoma 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Head and Neck Neoplasms 2Uterine Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Locoregional Recurrence 1

Interventions

Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced/Metastatic Solid Tumors × Fulvestrant × 90 days × Clear all
NCT07480681 2026-03-18

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Shanghai Henlius Biotech

Phase 1 Not yet recruiting
138 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡